Overview
Most metabolic-research compounds in this catalog are incretin-system agonists (GLP-1, GIP, and glucagon-receptor ligands) and related signaling molecules. The published literature studies them for metabolic and body-composition research endpoints. This guide describes how the compound is characterized and what that research covers. It is not usage guidance and makes no claim about outcomes from use.
A GLP-1 and glucagon receptor dual agonist studied primarily in metabolic research programs.
Evidence at a glance: Includes human-trial data
The cited record for this compound includes human-trial data. Each claim below still states its study type and population, so the scope of that evidence stays explicit.
Molecular identity
- Molecular formula
- C202H318N48O61
- Molecular weight
- 4404.9 g/mol
- CAS number
- 2609174-40-3
- Amino acids
- 29
- Appearance
- White lyophilized powder
- Purity (HPLC)
- 98.9%
Researched mechanism
Dual GLP-1/glucagon receptor agonism, related in class to other glucagon-containing agonists.
Described as a mechanism characterized in the literature, not an effect you should expect from use.
What the published research shows
Characterized in early-phase metabolic trials.
Honest note on evidence: Human literature is limited; the profile above reflects early-phase and mechanistic data only.
Every citation states its study type and population, so preclinical data is never presented as human-efficacy evidence.
How it compares
| Versus | Attribute | Note |
|---|---|---|
| Survodutide | Class | Both are GLP-1/glucagon dual agonists with differing sequences. |
Reconstitution
Concentration math only: adding bacteriostatic water to the vial gives the resulting mg/mL shown below. This is not usage guidance.
| Vial | Bacteriostatic water | Concentration |
|---|---|---|
| 5 mg | 1 mL | 5 mg/mL |
| 10 mg | 1 mL | 10 mg/mL |
Storage & stability
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (unopened) | -20°C | 24 months |
| Reconstituted | 2–8°C | up to 4 weeks |
Common questions
How does it differ from survodutide?+
Both target GLP-1 and glucagon receptors; sequences and pharmacokinetics differ. See the comparison table.
